DXB – Dimerix Ltd


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 1

Company Profile

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for focal segmental glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and diabetic kidney disease, and DMX-700 for chronic obstructive pulmonary disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. It has progressed to Phase III studies in FSGS, COVID-19 pneumonia feasibility and respiratory complications associated with COVID-19 feasibility. It is also planning for the next development stage in diabetic kidney disease and enters pre-clinical studies with DMX-700 for COPD.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan